1. Home
  2. TCRT vs PMCB Comparison

TCRT vs PMCB Comparison

Compare TCRT & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.72

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.93

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCRT
PMCB
Founded
1998
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
8.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TCRT
PMCB
Price
$2.72
$0.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
51.9K
406.0K
Earning Date
11-14-2025
12-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,000.00
N/A
Revenue This Year
$5,680,500.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.63
52 Week High
$6.20
$1.90

Technical Indicators

Market Signals
Indicator
TCRT
PMCB
Relative Strength Index (RSI) N/A 59.71
Support Level N/A $0.81
Resistance Level N/A $0.93
Average True Range (ATR) 0.00 0.09
MACD 0.00 0.02
Stochastic Oscillator 0.00 92.19

Price Performance

Historical Comparison
TCRT
PMCB

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: